JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB9561

Anti-PF4 抗体

Anti-PF4 antibody

4

(1 Review)

|

(14 Publications)

Rabbit Polyclonal PF4 antibody. Suitable for WB, sELISA and reacts with Human samples. Cited in 14 publications. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human PF4.

別名を表示する

CXCL4, SCYB4, PF4, Platelet factor 4, PF-4, C-X-C motif chemokine 4, Iroplact, Oncostatin-A

2 Images
Sandwich ELISA - Anti-PF4 antibody (AB9561)
  • sELISA

Unknown

Sandwich ELISA - Anti-PF4 antibody (AB9561)

To detect Human PF-4 by sandwich ELISA (using 100μl/well) a concentration of 0.5-2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with suitable detection antibody, allows the detection of at least 2000-4000 pg/ml of Recombinant Human PF-4.

Western blot - Anti-PF4 antibody (AB9561)
  • WB

Unknown

Western blot - Anti-PF4 antibody (AB9561)

All lanes:

Western blot - Anti-PF4 antibody (ab9561) at 1 µg/mL

All lanes:

Human Platelet (Human adult normal cell line) Whole Cell Lysate at 10 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-preadsorbed-ab97080'>ab97080</a>) at 1/5000 dilution

Predicted band size: 11 kDa

Observed band size: 11 kDa,18 kDa,30 kDa,37 kDa

true

Exposure time: 2min

Key facts

宿主種

Rabbit

クローン性

Polyclonal

アイソタイプ

Unknown

軽鎖のタイプ

unknown

キャリアフリー

No

交差種

Human

アプリケーション

WB, sELISA

applications

免疫原

Recombinant Full Length Protein corresponding to Human PF4.

P02776

style
left-column

代替製品

Primary Antibodies

AB129183

Anti-PF4 antibody [EPR7763]

20ul selling size|RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PF4 antibody [EPR7763] (AB129183)

  • 5
  • 1
Primary Antibodies

AB49735

Anti-PF4 antibody [RTO]

Western blot - Anti-PF4 antibody [RTO] (AB49735)

  • 0
  • 0
Primary Antibodies

AB129090

Anti-PF4 antibody [EPR7762]

RabMAb|Recombinant

Western blot - Anti-PF4 antibody [EPR7762] (AB129090)

  • 0
  • 0
Primary Antibodies

AB182988

Anti-PF4 antibody [EPR17279-1]

BOND RX™ Validated|RabMAb|Recombinant|Trial Size

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PF4 antibody [EPR17279-1] (AB182988)

  • 0
  • 0
Primary Antibodies

AB227485

Anti-PF4 antibody [EPR17279-1] - BSA and Azide free

BOND RX™ Validated|RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PF4 antibody [EPR17279-1] - BSA and Azide free (AB227485)

  • 0
  • 0

組合せ製品

Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

  • 5
  • 20
Assay Kits

AB189573

Human PF4 ELISA Kit (CXCL4)

Recombinant|SimpleStep

ELISA - Human PF4 ELISA Kit (CXCL4) (AB189573)

  • 0
  • 0
Primary Antibodies

AB181298

Anti-Leptin antibody [EPR16848-34]

RabMAb|Recombinant

Blocking - Anti-Leptin antibody [EPR16848-34] (AB181298)

  • 0
  • 0
Primary Antibodies

AB133347

Anti-Adiponectin antibody [EPR3218]

20ul selling size|RabMAb|Recombinant

Western blot - Anti-Adiponectin antibody [EPR3218] (AB133347)

  • 0
  • 0
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "sELISA" : {"fullname" : "Sandwich ELISA", "shortname":"sELISA"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p>To detect hPF-4 by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hPF-4 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.</p>", "sELISA-species-checked": "testedAndGuaranteed", "sELISA-species-dilution-info": "", "sELISA-species-notes": "<p>Can be paired for Sandwich ELISA with ab83123</p>" } } }
style
left-column

製品の詳細

This product is no longer batch tested in IHC, for an IHC validated antibody please see ab49735
style
left-column

出荷温度及び保存条件

製品の状態
Lyophilized
再構成
Reconstitute with 200µl of sterile water. Please note that if you receive this product in liquid form it has already been reconstituted as described and no further reconstitution is necessary.
精製方法
Affinity purification Immunogen
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
style
left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

The protein Platelet Factor 4 (PF4) also known as CXCL4 is a member of the chemokine (C-X-C motif) ligand family. This small protein has a molecular weight of approximately 7.8 kDa. PF4 is mainly expressed in megakaryocytes and stored in the alpha granules of platelets. During platelet activation PF4 releases into the bloodstream where it interacts with other proteins and cell types. Researchers measure PF4 levels with methods such as PF4 ELISA to study its expression and functions under various physiological and pathological conditions.
Biological function summary

PF4 plays an important role in modulating the immune response and coagulation processes. PF4 is not part of a stable protein complex but can interact dynamically with heparin on the surface of endothelial cells and glycosaminoglycans. It inhibits the action of heparin promoting clot formation and angiogenesis. PF4 also attracts and activates different types of leukocytes and can regulate inflammatory processes influencing how the immune system responds to injury.

Pathways

PF4 significantly interacts with both the coagulation and inflammation pathways. In the coagulation pathway PF4 acts to neutralize heparin-like molecules thereby enhancing thrombosis. It works closely with proteins such as thrombin and fibrinogen contributing to the blood clot cascade. Within the inflammatory pathway PF4's chemokine activity helps direct leukocytes to sites of tissue damage or infection linking it to cytokines and other chemokines that mediate immune responses.

Researchers associate PF4 with conditions such as thrombosis and autoimmune pathologies. In thrombosis the overexpression of PF4 can lead to excessive clot formation pointing to its interaction with proteins like thrombin. PF4 also plays a role in heparin-induced thrombocytopenia (HIT) a disorder where the immune system mistakenly produces antibodies against heparin-PF4 complexes further indicating its direct involvement with immune and coagulation pathways.
style
left-column
style
left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

ターゲットの情報

Chemokine released during platelet aggregation that plays a role in different biological processes including hematopoiesis, cell proliferation, differentiation, and activation (PubMed : 29930254, PubMed : 9531587). Acts via different functional receptors including CCR1, CXCR3A or CXCR3B (PubMed : 18174362, PubMed : 29930254). Upon interaction with CXCR3A receptor, induces activated T-lymphocytes migration mediated via downstream Ras/extracellular signal-regulated kinase (ERK) signaling (PubMed : 18174362, PubMed : 24469069). Neutralizes the anticoagulant effect of heparin by binding more strongly to heparin than to the chondroitin-4-sulfate chains of the carrier molecule. Plays a role in the inhibition of hematopoiesis and in the maintenance of hematopoietic stem cell (HSC) quiescence (PubMed : 9531587). Chemotactic for neutrophils and monocytes via CCR1 (PubMed : 29930254). Inhibits endothelial cell proliferation. In cooperation with toll-like receptor 8/TLR8, induces chromatin remodeling and activates inflammatory gene expression via the TBK1-IRF5 axis (PubMed : 35701499). In addition, induces myofibroblast differentiation and collagen synthesis in different precursor cells, including endothelial cells, by stimulating endothelial-to-mesenchymal transition (PubMed : 34986347). Interacts with thrombomodulin/THBD to enhance the activation of protein C and thus potentiates its anticoagulant activity (PubMed : 9395524).
See full target information PF4
style
left-column

文献 (14)

Recent publications for all applications. Explore the full list and refine your search

Biomolecules & biomedicine 25:1322-1334 PubMed39601768

2024

PF4 regulates neuronal ferroptosis in cerebral hemorrhage through CXCR3/PI3K/AKT/Nrf2 pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Na Hu,Yunfeng Li,Guohong Zhang,Wei Wang,Liping An,Ran An,Yu Liu

International journal of molecular sciences 24: PubMed36614095

2022

CXCL4-RNA Complexes Circulate in Systemic Sclerosis and Amplify Inflammatory/Pro-Fibrotic Responses by Myeloid Dendritic Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Immacolata Pietraforte,Alessia Butera,Lucia Gaddini,Anna Mennella,Raffaella Palazzo,Doriana Campanile,Katia Stefanantoni,Valeria Riccieri,Roberto Lande,Loredana Frasca

mAbs 13:1887628 PubMed33596779

2021

Off-target binding of an anti-amyloid beta monoclonal antibody to platelet factor 4 causes acute and chronic toxicity in cynomolgus monkeys.

Applications

Unspecified application

Species

Unspecified reactive species

Lise I Loberg,Meha Chhaya,Alexander Ibraghimov,Edit Tarcsa,Andreas Striebinger,Andreas Popp,Lili Huang,Frank Oellien,Stefan Barghorn

Annals of palliative medicine 9:2723-2730 PubMed32954739

2020

The anti-CXCL4 antibody depletes CD4(+)CD25(+)FOXP3(+) regulatory T cells in CD4+ T cells from chronic osteomyelitis patients by the STAT5 pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Kai Huang,Shuyu Ge

Cell reports 28:896-908.e5 PubMed31340152

2019

Platelets Promote Macrophage Polarization toward Pro-inflammatory Phenotype and Increase Survival of Septic Mice.

Applications

Unspecified application

Species

Unspecified reactive species

Agostina Carestia,Hebe A Mena,Cinthia M Olexen,Juan M Ortiz Wilczyñski,Soledad Negrotto,Andrea E Errasti,Ricardo M Gómez,Craig N Jenne,Eugenio A Carrera Silva,Mirta Schattner

Nature communications 10:1731 PubMed31043596

2019

CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-α production in systemic sclerosis.

Applications

Unspecified application

Species

Unspecified reactive species

Roberto Lande,Ernest Y Lee,Raffaella Palazzo,Barbara Marinari,Immacolata Pietraforte,Giancarlo Santiago Santos,Yves Mattenberger,Francesca Spadaro,Katia Stefanantoni,Nicoletta Iannace,Aleksandra Maria Dufour,Mario Falchi,Manuela Bianco,Elisabetta Botti,Luca Bianchi,Montserrat Alvarez,Valeria Riccieri,Marie-Elise Truchetet,Gerard C L Wong,Carlo Chizzolini,Loredana Frasca

Scientific reports 9:6059 PubMed30988349

2019

Platelet proteome reveals specific proteins associated with platelet activation and the hypercoagulable state in β-thalassmia/HbE patients.

Applications

Unspecified application

Species

Unspecified reactive species

Puangpaka Chanpeng,Saovaros Svasti,Kittiphong Paiboonsukwong,Duncan R Smith,Kamonlak Leecharoenkiat

JCI insight 3: PubMed30232279

2018

Neutrophil accumulation and NET release contribute to thrombosis in HIT.

Applications

Unspecified application

Species

Unspecified reactive species

Kandace Gollomp,Minna Kim,Ian Johnston,Vincent Hayes,John Welsh,Gowthami M Arepally,Mark Kahn,Michele P Lambert,Adam Cuker,Douglas B Cines,Lubica Rauova,M Anna Kowalska,Mortimer Poncz

The Journal of clinical endocrinology and metabolism 102:1851-1860 PubMed28323919

2017

Steroids Regulate CXCL4 in the Human Endometrium During Menstruation to Enable Efficient Endometrial Repair.

Applications

Unspecified application

Species

Unspecified reactive species

Jacqueline A Maybin,Uma Thiruchelvam,Mayank Madhra,Philippa T K Saunders,Hilary O D Critchley

Arthritis research & therapy 18:191 PubMed27558507

2016

Reduced induction of anti-PF4/heparin antibody in RA patients after total knee arthroplasty.

Applications

Unspecified application

Species

Human

Masahiro Izumi,Tatsuya Sakai,Atsunori Shirakawa,Hideko Kozuru,Yuka Jiuchi,Yasumori Izumi,Tomohiko Asahara,Kenji Kumagai,Masaaki Mawatari,Makoto Osaki,Satoru Motokawa,Kiyoshi Migita
View all publications
style
left-column
style
left-column
style
right-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com